Thanks to all contributors, and especially the last few reasoned posts from @TonyWAIW
Jon Pilcher and team have a statutory requirement to maximise shareholder value. IMO however, this does not necessarily mean waiting for all 4 trials to read out.
With regards to mergers, acquisitions and takeover offers, he must consider risk/reward scenarios with regards to the potential for a trial or multiple trial failures in the next 3 readouts.
It would be a dereliction of duties for him to blindingly assume that the next 3 readouts will all be stunning successes. History is littered with unexpected results from human clinical trials.
My point is, would shareholders prefer to accept a $50 -$60 takeover offer after the next (hopefully) positive readout, or see the stock pull back to $30 - $35 later this year if last 2 trials are unexpected failures.
It’s all about balance and risk/reward for Jon and team, and not trying to eek out every cent of blue sky before selling. I trust JP to make the right call.
GLTAH
- Forums
- ASX - By Stock
- NEU
- Share Price
Share Price, page-9193
-
- There are more pages in this discussion • 2,538 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$13.56 |
Change
-0.360(2.59%) |
Mkt cap ! $1.733B |
Open | High | Low | Value | Volume |
$13.94 | $13.96 | $13.50 | $6.421M | 470.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 1643 | $13.54 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.61 | 3100 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3723 | 13.510 |
5 | 2576 | 13.500 |
1 | 1000 | 13.450 |
1 | 223 | 13.420 |
3 | 299 | 13.390 |
Price($) | Vol. | No. |
---|---|---|
13.900 | 242 | 1 |
13.920 | 650 | 1 |
13.960 | 47 | 1 |
14.000 | 1020 | 2 |
14.120 | 493 | 1 |
Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |